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We here report a molecular basis for downregulation of interferon (IFN)-h production by V and C proteins of Sendai virus (SeV). The
infection of HeLa cells with SeV poorly induced IFN-h even if the expression of C/CV was disrupted. In contrast, when the expression of C/
CV/Y1/Y2 or V/W was disrupted, SeV infection strongly induced IFN-h production and significantly activated the interferon regulatory factor
(IRF)-3 pathway. The independent expression of C or V inhibited the double-stranded (ds) RNA- or Newcastle disease virus (NDV)-induced
activation of IRF-3 and NF-nB, as well as the IFN-h promoter. This inhibitory effect was also observed when Y1, Y2, or a C-terminal half
fragment (aa 85–204) of C was independently expressed. Phosphorylation and homodimer formation of IRF-3 were suppressed not only in
cells infected with SeV capable of expressing both C/CV/Y1/Y2 (or Y1/Y2) and V/W, but also in HeLa cells constitutively expressing Y1.
These results suggest that C, Y1, Y2, and V block signaling pathways leading to IRF-3 activation to downregulate IFN-h production.
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Viruses have developed their own strategies for evading
the interferon (IFN) system and mostly encode specific viral
protein(s) functioning as an IFN antagonist. Extensive
studies on the paramyxovirus evasion of the host IFN
system have revealed that the IFN antagonist of Paramyx-
ovirinae is V or C protein encoded by the P gene (Garcia-
Sastre, 2001; Goodbourn et al., 2000; Gotoh et al., 2001,
2002). The Paramyxovirinae includes five genera: Rubula-
virus, Avulavirus, Morbillivirus, Henipavirus, and Respir-
ovirus. Rubulavirus [Simian virus (SV) 5, SV41, human
parainfluenza virus type (hPIV) 2, and mumps virus] and
Avulavirus [Newcastle disease virus (NDV)] V proteins
target the signal transducer and activator of transcription
(STAT) 1 or STAT2 for proteasome-mediated degradation,0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: bin@fmsrsa.fukui-med.ac.jp (B. Gotoh).thereby blocking IFN signaling (Andrejeva et al., 2002;
Didcock et al., 1999a, 1999b; Huang et al., 2003; Kubota et
al., 2001; Nishio et al., 2001; Parisien et al., 2001; Park et
al., 2003; Young et al., 2000). Henipavirus (Hendra virus
and Nipah virus) and Morbillivirus (measles virus) V
proteins also block IFN signaling in different ways without
leading to the degradation of STATs (Palosaari et al., 2003;
Park et al., 2003; Rodriguez et al., 2002, 2003; Takeuchi et
al., 2003; Yokota et al., 2003). Although all the V proteins
examined to date in the above four genera retain the ability
to inhibit IFN signaling, the V protein of the respirovirus,
Sendai virus (SeV), has lost this kind of comparable anti-
IFN ability (Gotoh et al., 1999), and instead, C protein has
evolved to counteract the host IFN system as a substitute for
V protein (Garcin et al., 1999; Gotoh et al., 1999). A target
of SeV C protein is also IFN signaling (Didcock et al.,
1999a; Garcin et al., 1999; Gotoh et al., 1999). The
blockade of IFN-a signaling and IFN-g signaling has been
recently explained by the inhibition of the IFN-a-stimu-
lated tyrosine phosphorylation of STAT2 and the preven-
tion of binding of the g-activated factor to g-activated
sequence sites through C-STAT1 interaction, respectively
Fig. 1. Induction of IFN-h by rSeV infection. (Panel A) HeLa cells were
infected with WT (closed circle), C/CV() (closed diamond), 4C() (closed
square), or V() (closed triangle) at a moi of 10, and the culture
supernatants were harvested at the indicated time points. Levels of human
IFN-h in the supernatants were determined by ELISA. (Panel B) HeLa cells
were transfected with pIFD(-125)lucter and pRL-TK-Luc. At 24 h after
transfection, the cells were mock-infected or infected with WT, C/CV(),
4C(), or V() at a moi of 10 and harvested at 18 h pi. Firefly luciferase
reporter activity in the cell extracts was measured and normalized to renilla
luciferase activity. As a negative control, the activity of the extract from
cells, which were transfected with pTA-Luc containing only the TATA box
of herpes simplex virus thymidine kinase promoter (TK TATA) and
subsequently infected with WT, is also indicated (B). Data represent the
mean values from triplicate samples (A and B). (Panel C) HeLa cells
infected with WT, 4C(), C/CV(), or V() were harvested at the indicated
time points. The cell extracts were then subjected to SDS–10% PAGE for
Western blot analysis with anti-SeV serum.
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Takeuchi et al., 2001).
SeV C protein is expressed from the P gene as a nested
set of four proteins, CV, C, Y1, and Y2, whose open reading
frame (ORF) overlaps the P ORF in the +1 frame (Curran
and Kolakofsky, 1989; Giorgi et al., 1983). Translation of
CV, C, Y1, and Y2 initiates at distinct positions, 81ACG,
114AUG, 183AUG, and 201AUG, respectively, but terminates
at the same position, 726UAA. Accordingly, these four
proteins have a common C-terminal region. C, Y1, and
Y2 are identical in their ability to inhibit IFN signaling as
well as an IFN-induced antiviral state (Gotoh et al., 2003b;
Kato et al., 2001, 2002). However, there is continuing
controversy as to the ability of the shorter form (Y1/Y2)
of the C protein to inhibit the IFN-induced antiviral state
(Garcin et al., 2001; Kato et al., 2001). Although the role of
C protein in evading the host IFN system has been partly
uncovered, the role of SeV V protein remains unknown.
SeV V protein is expressed from the editing transcript from
the P gene, and its C-terminal cysteine-rich region is highly
conserved among members of the Paramyxovirinae. This
suggests that SeV V protein may formerly have had a
similar anti-IFN ability to the V proteins of the other genera.
Thus, we speculated that SeV V protein might retain some
anti-IFN ability common to that of other genera. On the
other hand, the accumulated evidence had suggested that
several viruses had acquired the ability to downregulate IFN
production during evolution. For example, influenza virus
NS1 and Ebola virus VP35 proteins downregulate IFN
production by inhibiting IRF-3 activation or NF-nB activa-
tion (Basler et al., 2000; Talon et al., 2000). Human
papillomavirus type 16 E6 (Ronco et al., 1998) and human
herpesvirus-8 vIRF-1 (Lin et al., 2001) proteins also inhibit
the induction of IFN-h in different ways. We therefore
decided to examine the effect of SeV V and C proteins on
the induction of IFN-h.
The molecular basis for the IFN-h induction mechanism
has been extensively studied but is not yet fully understood.
Intracellular double-stranded (ds) RNA generated during
viral replication and transcription is thought to be an
important inducer of IFN-h. Virus infection or dsRNA
treatment leads to phosphorylation events that induce the
activation of latent transcription factors: nuclear factor
kappa beta (NF-nB), interferon regulatory factor (IRF)-3,
and ATF-2/c-Jun (for review, see Servant et al., 2002). The
activated NF-nB, ATF-2/c-Jun, and IRF-3 are cooperatively
assembled on the IFN-h promoter together with c-AMP
responsive element binding protein (CREB) binding protein
(CBP)/p300 and the high-mobility-group protein (HMG) I
(Y) and activate the transcription of the IFN-h gene (Mani-
atis et al., 1998). The IFN-h promoter contains four positive
regulatory domains (PRDs), designated PRDI through
PRDIV (Goodbourn et al., 2000). PRDI and PRDIII are
bound and activated by members of the IRF family includ-
ing IRF-3 and IRF-7 (Lin et al., 1998; Sato et al., 1998;
Schafer et al., 1998; Wathelet et al., 1998; Weaver et al.,
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by NF-nB (Lenardo et al., 1989; Visvanathan and Good-
bourn, 1989), whereas PRDIV is bound and activated by
ATF-2/c-Jun (Du and Maniatis, 1992; Du et al., 1993).
IRF-3 plays a crucial role in the virus-induced activation
of the IFN-h promoter (Sato et al., 2000; Taniguchi et al.,
2001; Yoneyama et al., 2002). Upon virus infection or
dsRNA treatment, IRF-3 is phosphorylated on serine and
threonine residues in the C-terminal domain (Lin et al.,
1998; Wathelet et al., 1998; Weaver et al., 1998; Yoneyama
et al., 1998) by IKKq and TANK binding kinase (TBK) 1
(Fitzgerald et al., 2003; Sharma et al., 2003), forms a
homodimer, and translocates into the nucleus. IRF-3 is
ubiquitously expressed in the cytoplasm and its expression
is not altered by IFN treatment or virus infection, whereas
IRF-7 is expressed at very low basal levels and is induced
by IFN treatment. IRF-7 is therefore considered to function
in the late amplification phase of the gene activation of IFN-
a subspecies and IFN-h. NF-nB is present in a quiescent
state in the cytoplasm in association with inhibitor kappa B
(InB). Virus infection or dsRNA treatment causes the
phosphorylation of InB by InB kinase (IKK) complex
consisting of IKKa, IKKh, and IKKg. The phosphorylated
InB is destroyed through proteasome-mediated degradation,
resulting in the translocation of freed NF-nB into the
nucleus (Karin and Ben-Neriah, 2000). Virus infection or
dsRNA treatment also activates c-Jun amino terminal
kinases (JNKs) and p38 proteins, which in turn activate
ATF-2 and c-Jun through phosphorylation (Chu et al., 1999;
Iordanov et al., 2000).
This paper reports the molecular basis for the negative
regulation of IFN-h production by SeV C and V proteins.Fig. 2. Four overlapping PRDs in the IFN-h promoter and the construct of pPRDIV
are bound by members of the IRF family, including IRF-3 and IRF-7. PRDII is bo
bound and activated by ATF-2/c-Jun. The HMG I (Y) binds to PRDII and PRD
interact with each other and with ATF-2, c-Jun, NF-nB p65, and IRFs (IRF-3 and
also indicated. TK TATA; the TATA box of herpes simplex virus thymidine kinaDuring our research, Pool et al. and He et al. demonstrated
that SV5 V protein inhibited induction of IFN-h by block-
ing the IRF-3 and NF-nB pathways and further showed a
similar inhibitory effect of SeV and hPIV2 V proteins on
dsRNA-induced activation of the IFN-h promoter. Our
results not only support their findings but also demonstrate
that SeV C protein, as well as V protein, blocks signaling
pathways leading to the activation of IRF-3 and NF-nB. The
domain of C protein, responsible for this blockade, has been
mapped to the C-terminal half region encompassed by the
shorter form (Y1/Y2) of C protein.Results
Both C/C V/Y1/Y2 and V/W function as negative regulators
for SeV-induced IFN-b production
It has been reported that clinical isolates of the morbilli-
virus, measles virus, inhibit the virus-induced production of
IFN (Naniche et al., 2000). This report prompted us to
define the role of the SeV accessory V and C proteins in
IFN-h production. We used recombinant SeVs (rSeVs) with
knocked out accessory proteins: 4C() that expresses none
of the four C proteins (CV, C, Y1, and Y2), C/CV() that
expresses neither C nor CV but expresses both Y1 and Y2,
and V() that expresses neither V nor W (Kato et al.,
1997a; Kurotani et al., 1998). HeLa cells were infected with
either wild-type rSeV (WT), 4C(), C/CV(), or V(), and
the levels of IFN-h in the culture supernatants were deter-
mined by ELISA. As shown in Fig. 1A, whereas WT and C/
CV() were poor inducers of IFN-h, infection of HeLa cells-Luc, pPRDI/III-Luc, and pPRDII-Luc reporter plasmids. PRDI and PRDIII
und and activated by NF-nB consisting of p50 and p65, whereas PRDIV is
IV cooperatively with NF-nB (p65/p50) and ATF-2/c-Jun. p300 and CBP
IRF-7). NRDI; negative regulatory domain I. The construct of pTA-Luc is
se promoter.
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from the early phase of infection. To define whether the
difference in IFN-h production would reflect the difference
in the activation of an IFN-h promoter, we carried out
reporter gene assays using pIFD(125)lucter, a plasmid that
expresses a firefly luciferase under the control of the IFN-h
promoter (King and Goodbourn, 1994). As shown in Fig.
1B, the IFN-h promoter was markedly activated by 4C()
or V() infection but not by WT or C/CV() infection.
These results indicate that C/CV/Y1/Y2 as well as V/W
negatively regulate the SeV-induced activation of the IFN-
h promoter and consequently suppress IFN-h production. It
should be noted that C/CV() retains the ability to inhibit
IFN-h induction as efficiently as WT (Figs. 1A, B). This
indicates that Y1 and Y2 can compensate for the lack of C
and CV in the context of SeV infection.
The negative regulation of IFN-h induction in the
presence of C/CV/Y1/Y2 and V/W may be a simple conse-
quence of the downregulation of viral replication andFig. 3. Inhibition of activation of IRF-3 in WT and C/CV()-infected cells. pPRDI/
reporter plasmid to detect the activation of IRF-3, NF-nB, and ATF-2/c-Jun, res
pPRDI/III-Luc, pPRDII-Luc, or pPRDIV-Luc together with pRL-TK-Luc. At 24 h
4C(), C/CV(), or V() at a moi of 10 and harvested at 18 h pi. Firefly luciferase
luciferase activity. As a negative control, the activities of the extract from cells, wh
WT, are also indicated. Data represent the mean values of the normalized lucifertranscription that would possibly determine the quantity
of an IFN-h inducer such as dsRNA. Indeed, viral protein
synthesis was enhanced in the V()-infected cells although
it was reduced in the 4C()- or C/CV()-infected cells (Fig.
1C). This suggests that the V/W may downregulate IFN-h
induction in part by reducing the quantity of the IFN-h
inducer.
SeV infection significantly activates the IRF-3 pathway in
the absence of C/C V/Y1/Y2 or V/W
The IFN-h promoter consists of four distinct positive
regulatory domains (PRDs) shown in Fig. 2 (Maniatis et al.,
1998). PRDI and PRDIII are bound and activated by IRF-3.
PRDII is bound and activated by NF-nB, whereas PRDIV is
bound and activated by an ATF-2/c-Jun heterodimer. To
evaluate the activation of IRF-3, NF-nB, and ATF-2/c-Jun,
reporter gene assays were carried out using IRF-3 respon-
sive reporter pPRDI/III-Luc, NF-nB responsive reporterIII-Luc (A, D), pPRDII-Luc (B, E), and pPRDIV-Luc (C, F) were used as a
pectively. HeLa (A–C) or Vero (D–F) cells were transfected with either
after transfection, the cells were mock-infected or infected with either WT,
reporter activity in the cell extracts was measured and normalized to renilla
ich were transfected with pTA-Luc (TATA) and subsequently infected with
ase activities from triplicate samples.
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Luc, respectively (Fig. 3). The IRF-3 responsive promoter
was efficiently activated by the infection of HeLa cells with
4C() or V(), whereas the WT or C/CV() infection
poorly activated this promoter (Fig. 3A). The activation
profile paralleled that of the IFN-h promoter (Fig. 1B). A
similar activation profile was observed in the NF-nB re-
sponsive promoter, but the difference in the NF-nB activa-
tion level among the rSeVs was not so striking (Fig. 3B). As
reported in SV5 (Poole et al., 2002), the ATF-2/c-Jun
responsive promoter was hardly activated by any of the
rSeVs tested (Fig. 3C). These results suggest that the major
target of C/CV/Y1/Y2 and V/W for preventing IFN-h induc-
tion is the IRF-3 pathway. Because there are several
members of the IRF family, including IRF-3, that can bind
and activate the PRDI/III construct, additional experiments
were conducted to specify the importance of the IRF-3
pathway. First, we carried out reporter gene assays in Vero
cells (non-IFN producer cell line) instead of HeLa cells (IFN
producer cell line). Similar results were obtained in Vero
cells (Figs. 3D–F), suggesting that the factor that binds and
activates the PRDI/III construct is IRF-3 rather than IFN-a/
h-induced factors such as IRF-7 or ISGF-3. Second, weFig. 4. Effect of the expression of IRF-3 and IRF-3DN on 4C() or V()-
induced activation of the IFN-h promoter. HeLa cells were transfected with
combinations of a reporter plasmid pIFD(-125)lucter and an expression
plasmid [either pKS336 empty vector (vec), pKS-IRF-3 (IRF-3), or pKS-
IRF-3DN (IRF-3DN)] together with pRL-TK-Luc. At 20 h after transfec-
tion, the cells were infected with either 4C() (A) or V() (B) at a moi of
10. At 18 h pi, the cells were harvested and measured for luciferase activity.
Firefly luciferase reporter activity in the cell extracts was normalized to
renilla luciferase activity. Data represent the mean values of the normalized
luciferase activities from triplicate samples. Asterisks indicate a significant
difference from the control vec + (*P < 0.05, ** P < 0.01, Student’s t test).
Fig. 5. Effect of C, V, or truncated C proteins on the dsRNA-induced
activation of the IFN-h promoter (A), IRF-3 responsive promoter (B), or
NF-nB responsive promoter (C). HeLa cells were transfected with various
combinations of a reporter plasmid [either pIFD(-125)lucter (A), pPRDI/III-
Luc (B), or pPRDII-Luc (C)] and an expression plasmid [either pEFneo
empty vector (vec), pEFneo-C (C) (aa 1–204), pEFneo-Y1 (Y1) (aa 24–
204), pEFneo-Y2 (Y2) (aa 30–204), pEFneo-D1 (D1) (aa 85–204),
pEFneo-D2 (D2) (aa 127–204), pEFneo-D3 (D3) (aa 30–126), or pEFneo-
V (V) (aa 1–384)] together with pRL-TK-Luc. At 24 h after transfection,
the cells were mock-treated (open bar) or treated with poly (I)/poly (C)
(closed bar). At 6 h after the poly (I)/poly (C) treatment, the cells were
harvested and measured for luciferase activity. Firefly luciferase reporter
activity in the cell extracts was normalized to renilla luciferase activity.
Data represent the mean values of the normalized luciferase activities from
triplicate samples. Asterisks indicate a significant difference from the
control vec + (*P < 0.05, ** P < 0.01, Student’s t test).examined the effect of the overexpression of IRF-3 and the
dominant negative mutant of IRF3, IRF-3DN (an N-termi-
nally truncated IRF-3), lacking most of the DNA binding
domain, on the V()- or 4C()-induced activation of the
IFN-h promoter. Overexpression of IRF-3 in 4C() or V()
virus-infected cells enhanced the activation of the promoter,
whereas the expression of IRF-3DN dramatically reduced
the promoter activation (Fig. 4). These results suggest that
both 4C() and V() infections activate the IFN-h pro-
moter in an IRF-3-dependent manner.
Fig. 6. Inhibition of NDV-mediated production of IFN-h, IL-6, and
RANTES in HeLa-C or HeLa-Y1. (Panel A) HeLa-vec, HeLa-C, and HeLa-
Y1 were infected with NDV at a moi of 10. The supernatants were
harvested at 18 pi and measured for the level of human IFN-h. Data of the
IFN-h levels represent the mean values from triplicate samples. (Panel B)
HeLa-vec and HeLa-Y1 were infected with NDV at a moi of 10. The
supernatants were harvested at 21 pi and measured for the level of human
IL-6 and RANTES.
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dsRNA-induced activation of the IFN-b promoter, IRF-3
responsive promoter, and NF-jB responsive promoter
How do C/CV/Y1/Y2 and V/W inhibit the IRF-3 path-
way? As described above, inhibition of the IRF-3 activation
by the V/W may be attributable to the possibly limited
generation of the IFN-h inducer (Fig. 1C). To determine
whether C and V proteins had the ability to block the
downstream signaling pathway of the IFN-h inducer gen-
eration step, we examined the effect of C and V on the
dsRNA-mediated induction of IFN-h (Fig. 5). HeLa cells
were transiently transfected with various combinations of a
plasmid, which expresses either C, V or truncated C pro-
teins, and one of the reporter plasmids: pIFD(-125)lucter,
pPRDI/III-Luc, and pPRDII-Luc. The cells were subse-
quently treated with dsRNA. As shown in Fig. 5, both C
and V could moderately suppress the dsRNA-mediated
activation of the IFN-h promoter as well as IRF-3 and
NF-nB responsive promoters without the aid of other viral
proteins (Figs. 5A–C). These results suggest that C and V
proteins target the dsRNA signaling pathway leading to the
activation of IRF-3 and NF-nB. The expression of Y1 (aa
24–204), Y2 (aa 30–204), or D1 (aa 85–204) exhibited a
suppressive effect comparable to that of the full-size C,
whereas the expression of D2 (aa 127–204) or D3 (aa 30–
126) did not. This demonstrates that the C-terminal half
fragment (aa 85–204) of C is responsible for the suppres-
sion of the dsRNA-induced activation of the IFN-h pro-
moter. When NDV was used as an IFN-h stimulator instead
of dsRNA or when Vero cells were used instead of HeLa
cells, similar results were obtained (data not shown). Be-
cause SeVs including 4C() cannot replicate efficiently
when a large amount of the C protein is present intracellu-
larly before infection (Kato et al., 2001), 4C() could not be
used instead of NDV.
To obtain further evidence for the ability of C protein to
inhibit the IRF-3 and NF-nB pathways, we next examined
effect of C protein on IRF-3 or NF-nB-mediated activation
of other endogenous genes such as the CC chemokine
RANTES and interleukin (IL)-6. Previously established
HeLa-C or HeLa-Y1, which constitutively expresses
RGSH6 epitope tagged C or Y1, respectively (Gotoh et
al., 2003b), was infected with NDV, and thereafter, each
supernatant was assayed for the level of IFN-h. As shown in
Fig. 6A, production of IFN-h was suppressed in both HeLa-
C and HeLa-Y1, but the suppression in HeLa-C was
insufficient probably due to the low expression of C, whose
level is about 0.37-fold as high as that of Y1 (Gotoh et al.,
2003a, 2003b). Production of (NF-nB-dependent) IL-6 as
well as (IRF-3 and NF-nB dependent) RANTES was thus
compared between HeLa-Y1 and control HeLa. As shown
in Fig. 6B, production of IL-6 and RANTES in response to
NDV infection was also suppressed in HeLa-Y1, supporting
the idea that C protein inhibits the IRF-3 and NF-nB
pathways.
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We next determined whether C/CV/Y1/Y2 and V/W could
inhibit phosphorylation and dimerization of IRF-3. Dimeric
and monomeric forms of IRF-3 are readily detectable by
native polyacrylamide gel electrophoresis (PAGE) in the
presence of 1% deoxycholate (DOC) (Iwamura et al., 2001;
Suhara et al., 2000), while phosphorylation status of IRF-3
can be monitored by its decreased mobility in sodium
dodecyl sulfate (SDS)-PAGE (Lin et al., 1998; Yoneyama
et al., 1998). As shown in Figs. 7A, B, the dimer formation
and phosphorylation of IRF-3 were unequivocally enhanced
in the 4C()- or V()-infected cells (Figs. 7A, B, lanes 2–
4). To confirm the ability of C protein to inhibit the
phosphorylation and dimerization of IRF-3, HeLa-Y1 was
infected with NDV (Figs. 7C, D) or treated with dsRNA
(Figs. 7E, F) and then examined for the dimer formation and
phosphorylation of IRF-3. As shown in Figs. 7C–F, the
dimer formation and phosphorylation of IRF-3 were signif-
icantly suppressed in HeLa-Y1. Taken together, these results
suggest that both C/CV/Y1/Y2 and V/W target the signaling
pathway leading to IRF-3 phosphorylation for the down-
regulation of IFN-h production.Discussion
The SeV accessory proteins, both C and V, play impor-
tant roles in virus growth and pathogenesis in vivo (Delenda
et al., 1998; Hasan et al., 2000; Kato et al., 1997a, 1997b;
Kurotani et al., 1998; Latorre et al., 1998). C protein is a
Fig. 7. Inhibition of dimer formation and phosphorylation of IRF-3 by C or V protein. (Panels A and B) HeLa cells were mock-infected or infected with either
WT, C/CV(), 4C(), or V() at a moi of 10 and harvested at indicated times. Extracts from the cells were subjected to native PAGE (A) or SDS–7.5% PAGE
(B) for Western blotting with an anti-IRF-3 antibody. (Panels C–F) HeLa-vec and HeLa-Y1 cells were harvested at the indicated time points after NDV
infection (C, D) or poly (I)/poly (C) treatment (E, F). The cell extracts were then subjected to native PAGE (C, E) or SDS–7.5% PAGE (D, F) for Western
blotting with an anti-IRF-3 antibody. Arrows (A, C, E) indicate the positions of the IRF-3 monomer (m) and IRF-3 homodimer (d).
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scription and replication (Cadd et al., 1996; Curran et al.,
1992; Tapparel et al., 1997), but also facilitates virus
assembly, assists in virion morphogenesis (Hasan et al.,
2000), and inhibits IFN-stimulated gene transcription (Did-
cock et al., 1999a; Garcin et al., 1999; Gotoh et al., 1999;
Yokoo et al., 1999). Whereas the versatile functions of C
protein had been uncovered, the functions of V protein in a
virus life cycle had remained obscure. The present study has
shed light on a novel function of C and V proteins as
negative regulators of IFN-h production.
During our research, three related papers were pub-
lished (He et al., 2002; Poole et al., 2002; Strahle et al.,
2003). Strahle et al. compared the abilities of several
mutant rSeVs to induce various cytokines, such as IFN-
h. These rSeVs include SeV-CD10-15, which expresses Y1
and Y2 besides C and CV mutant proteins with the deletion
of six amino acids present on only the larger pair of Cproteins, SeV-CF170S, which has F170S mutation on the C
protein, and SeV-V/W++, which contains a stop codon at
the beginning of the V ORF. They showed that these
rSeVs more significantly induced IFN-h than the wild
type, and suggested the involvement of C and V proteins
in the negative regulation of IFN-h induction. Their study,
however, did not exclude the possibility that negative
regulation may be only a secondary consequence of the
limitation of the generation of the IFN-h inducer due to
the downregulation of viral replication and transcription by
the accessory proteins (Cadd et al., 1996; Curran et al.,
1992; Kato et al., 1997a, 2001; Tapparel et al., 1997). The
present study has demonstrated for the first time that C
protein has the intrinsic ability to suppress the dsRNA- or
NDV-induced activation of IRF-3 and NF-nB, which are
crucial for the activation of the IFN-h promoter. Our
results, however, do not negate the possibility that both
accessory proteins may target multiple events including the
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signaling pathway. Pool et al. and He et al. first identified
a paramyxovirus protein responsible for the downregula-
tion of IFN-h production (He et al., 2002; Poole et al.,
2002). Their reports have revealed that the V protein of
SV5 inhibits the activation of IRF-3 and NF-nB, and
downregulates IFN-h induction. They further demonstrated
the ability of the hPIV2 and SeV V proteins to inhibit
dsRNA-induced IFN-h promoter activation. Our study not
only confirms their findings but also demonstrates the
similarity between SeV and SV5 V proteins in the under-
lying molecular mechanism (Fig. 5). The similarity sug-
gests that the common ancestor of the respirovirus SeV V
protein and the rubulavirus SV5 V protein may have
already acquired this kind of anti-IFN ability. The ATF-
2/c-Jun pathway does not seem particularly important for
the SeV-mediated induction of IFN-h (Fig. 3C) as well as
the SV5-mediated induction of IFN-h (Poole et al., 2002).
Although wild-type SV5 efficiently suppresses NF-nB
activation (Poole et al., 2002), the suppression by wild-
type SeV was not so significant (Fig. 3B). Therefore, the
ability of SeV C and V proteins to suppress NF-nB
activation may not so greatly contribute to the negative
regulation of IFN-h production in the context of SeV
infection (Fig. 3B).
PRDI/III reporter assays (Fig. 3) and dominant negative
IRF-3 experiments (Fig. 4) suggest that production of IFN-h
in 4C()- and V()-infected cells is enhanced in an IRF-3
dependent manner. However, these experiments do not
exclude the possibility that other pathways are involved in
the enhancement of IFN-h induction, because IRF-3DN
may work by mopping up not only endogenous IRF-3 but
also other essential signaling molecules or transcriptional
cofactors that interact with IRF-3. Nevertheless, analyses of
IRF-3 phosphorylation and dimer formation reveal signifi-
cance of the IRF-3 pathway for the SeV downregulation of
IFN-h production (Fig. 7). How do C and V proteins
suppress the activation of IRF-3 and NF-nB? The expres-
sion level of C in HeLa-C is sufficient to block IFN
signaling (Gotoh et al., 2003a, 2003b), but is insufficient
to suppress IFN-h production. This suggests that the mech-
anism by which C protein downregulates IFN-h production
is independent of the mechanism for the blockade of IFN-a
signaling.
V() or 4C() infection induces IFN-h more efficiently
than WT infection does (Figs. 1A, B), although V() or
4C() expresses CV/C/Y1/Y2 or V, respectively. Induction
of IFN-h is determined by balance of two variable factors
produced during infection: IFN-h inducers and viral IFN
antagonists, CV/C/Y1/Y2 and V. It is thus possible that subtle
change in kinetics of these factors’ generation greatly affects
IFN-h induction. Accordingly, enhanced IFN-h induction
observed in V()- or 4C()-infected cells does not neces-
sarily imply that CV/C/Y1/Y2 or V is unable to work as IFN
antagonists in the context of V() or 4C() infection.
Presumably, a double knockout virus, if could be created,would induce IFN-h more significantly than single knock-
out viruses, 4C() and V().
The ability of Y1, Y2, and D1 to inhibit the dsRNA- or
NDV-induced activation of IRF-3 and NF-nB as well as the
IFN-h promoter was comparable to that of full-size C (Fig.
5). These results demonstrate that the C-terminal half region
of C protein is responsible for the blockade of signaling
pathways leading to IFN-h induction. This may explain why
C/CV() was closer to WT rather than 4C() in IFN-h-
inducing capacity (Figs. 1A, B). On the contrary, Strahle et
al. (2003) showed that SeV-CD10-15, which can express Y1
and Y2, caused significant activation of the IFN-h promoter.
This result, however, does not necessarily conflict with our
results. Since the D10–15 mutation results in not only
deletion of aa 10–15 on C protein but also deletion of aa
13–18 on V protein, the significant induction of IFN-h by
CD10–15 may reflect the possible loss of the anti-IFN
activity of VD13–18 rather than the loss of the anti-IFN
activity of CD10–15 and CVD10–15.
SeV is often used as an IFN-h inducer, although SeV Z
strain used in this study was found to be a poor inducer. As
to this point, Poole et al. (2002) presented important data.
They showed that SeV stocks prepared by inoculation of
embryonated chicken eggs with a high dilution of viral stock
were intrinsically poor inducers, although SeV stocks con-
taining DI particles, which were prepared by serial passage
at low dilutions, became strong inducers. In addition to their
observation, we found a difference among SeV strains in the
ability to induce IFN-h. For example, SeV Nagoya strain
induced IFN-h earlier in infection, and the level of IFN-h at
36 h pi reached about 12 times higher than that in SeV Z
strain infected cells (unpublished result). Accordingly, SeV
stocks containing a notable quantity of DI particles, or
strong inducer strains like Nagoya strain, may have been
used so far extensively by many researchers as the IFN-h
inducer.
Koyama et al. have recently reported that SeV-induced
apoptosis was strikingly enhanced in the absence of C/CV/
Y1/Y2 and have concluded that C protein has anti-apoptotic
activity (Koyama et al., 2003). The activation of IRF-3 is
important for inducing apoptosis in the SeV-infected cells,
because SeV-induced apoptosis is blocked by the expression
of the dominant negative form IRF-3DN (Heylbroeck et al.,
2000). Thus, the ability of the accessory proteins to inhibit
the phosphorylation of IRF-3 may contribute to not only the
downregulation of IFN-h production but also the suppres-
sion of SeV-induced apoptosis, thereby sustaining efficient
virus growth.Materials and methods
Cells and viruses
HeLa and Vero cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
T. Komatsu et al. / Virology 325 (2004) 137–148 14510% fetal bovine serum (FBS). A HeLa-vec cell line was
isolated, which had survived geneticin (G418) (GIBCO
BRL) treatment after the transfection of HeLa cells with
an empty pEFneo vector. HeLa-C, HeLa-Y1, or HeLa-Y2,
which constitutively expresses the RGS-His epitope
(RGSH6) tagged C, Y1, or Y2, respectively (Gotoh et al.,
2003b), as well as HeLa-vec, was maintained in DMEM
supplemented with 10% FBS and 0.8 mg/ml G418. Recom-
binant SeVs, wild-type SeV (derived from Z strain), 4C(),
C/CV(), and V() (Kato et al., 1997a; Kurotani et al.,
1998), were propagated in Vero cells in the presence of
trypsin (Gotoh et al., 1999). NDV strain, La Sota, was
propagated in embryonated eggs as previously described
(Gotoh et al., 1992).
Plasmids
The reporter plasmid with a firefly luciferase gene under
the control of the human IFN-h promoter, pIFD(-125)lucter
(King and Goodbourn, 1994), was kindly provided by Dr.
S. Goodbourn. The PRD multimer reporters, pPRDI/III-
Luc, pPRDII-Luc, and pPRDIV-Luc, were newly created
by cloning the (PRDI/III)3, (PRDII)5, or (PRDIV)3 DNA
fragment between the NheI and BglII sites of pTA-Luc
(Promega). The (PRDI/III)3, (PRDII)5, or (PRDIV)3 DNA
fragment was generated by annealing a pair of synthetic
oligonucleotides, [5V-CTAGC(GAAAACTGAAAGGGA-
GAAGTGAAAGTG)3A-3V] and [5V-GATCT(CACTTT-
CACTTCTCCCTTTCAGTTTTC)3G-3V], a pair of [5V-
CTAGC(GGGAAATTCC)5A-3V] and [5V-GATCT(G-
GAATTTCCC)5G-3V], or a pair of [5V-CTAGC(TAAATGA-
CATAGGAAA)3A-3V] and [5V-GATCTT(TTTCCTA-
TGTCATTTA)3G-3V], respectively. The pRL-TK-Luc
(Clontech), which expresses renilla luciferase under the
control of the herpes simplex virus thymidine kinase
promoter, was used as an internal control for the reporter
gene assay. DNA fragments encoding IRF-3 and the
dominant negative form, IRF-3DN (Lin et al., 1998), were
amplified by PCR with the GST-IRF-3 expression plasmid
DNA (a gift from Dr. P. Pitha-Rowe) (Au et al., 2001) as a
template. Forward primers, IRF3-F [5V-AAGGTACCC
XhoIctcgagACCATGGGAACCCCAAAGCCACGGATC-3V]
and IRF3DN-F [5V-AAGGATCCXhoIctcgagACCATGGCC-
CCGAGGCCACTGGTGCATATGTT-3V] and a reverse
primer, IRF3-R [5V-TTAAGCTTNotIgcggccgcTCAT-
TCAGCTCTCCCCAGGGCCCTGGAA-3V], were used in
PCR for IRF-3 and IRF-3DN. Italics indicate nucleotide
sequences that are not involved in ORF. Restriction enzyme
recognition sites are in lowercase. The PCR-amplified
DNA was digested with XhoI and NotI restriction enzymes,
and then inserted into the corresponding site of pKS336
(GeneBank accession number AF403737) (a gift from Dr.
K. Sakai), an expression vector driven under the control of
the mammalian EF1a promoter. These plasmids were
termed pKS-IRF-3 and pKS-IRF-3DN, respectively. The
V DNA fragment was generated by two-step PCR-basedoverlap primer extension as described previously (Ho et al.,
1989). Briefly, two DNA fragments having overlapping
ends were generated by PCR with the template cDNA
clone H-33 (Shioda et al., 1983) (a gift from Dr. T. Shioda)
and two sets of a primer pair: (VF [5V-GAATTCBamHIggatc-
tccAGAGCATGGATCAAGATGCCT-3V] and VMR [5V-
TCTCCTATGCCCCTTTTTTGTTGAG-3V]) and (VMF
[5V-CTCAACAAAAAAGGGGCATAGGAGA-3V] and VR
[5V-AAAGCTTNotIgcggccgcGGATGGTAGGATGCCTCA-
3V]). The mutated nucleotides in the complementary pri-
mers, VMR and VMF, are underlined. The two PCR-
amplified fragments were combined in the subsequent
fusion reaction, digested with BamHI restriction enzyme,
and inserted between BamHI and EcoRV sites of pEFneo
(Asao and Fu, 2000) (a gift from H. Asao), another
expression vector driven under the control of the mamma-
lian EF1a promoter. To eliminate the ability to express C
proteins (CV, C, Y1, and Y2) from V mRNA, a termination
codon was introduced into the C ORF without affecting the
V amino acid sequence by using a site-directed mutagenesis
kit (Stratagene) with an oligonucleotide Ct [5V-213CGAGT-
CGAGTGAACCAACTGACATA232GGAGGGGACA-
GAAGC247-3V]. The introduced mutagenesis was
confirmed by the DNA sequencing. The amplified DNA
was digested with the BamHI restriction enzyme, and then
inserted between BamHI and EcoRV sites of pEFneo. This
plasmid was termed pEFneo-V. The plasmids expressing
His tag minus C and C mutant proteins (pEFneo-C,
pEFneo-Y1, pEFneo-Y2, pEFneo-D1, pEFneo-D2, and
pEFneo-D3) have been described previously (Gotoh et
al., 2003b). Pyrobest DNA polymerase (Takara Biomedi-
cals, Otsu Japan) was used for all PCRs.
Measurement of levels of IFN-b, RANTES, and IL-6 in
culture supernatants
Cells in 24-well plates were infected with rSeV or NDV
at a multiplicity of infection (moi) of 10, or treated with
synthetic dsRNA. For treatment with dsRNA, poly(I):po-
ly(C) was added directly to cells at a final concentration of
100 Ag/ml. The levels of human IFN-h, IL-6, and RANTES
in culture supernatants of cells were determined using a
human IFN-h ELISA kit (TFB Inc.), a human IL-6 immu-
noassay kit (BioSource International, Inc.), and a human
RANTES immunoassay kit (BioSource International, Inc.)
according to the manufacturers’ protocol.
Reporter gene assay
Subconfluent monolayers in 96-well plates were trans-
fected with various combinations of a reporter plasmid
[either pIFD(-125)lucter (50–100 ng/well), pPRDI/III-Luc
(25–50 ng/well), pPRDII-Luc (25–50 ng/well), or
pPRDIV-Luc (25–50 ng/well)] and an expression plasmid
[either pEFneo-C, pEFneo-Y1, pEFneo-Y2, pEFneo-D1,
pEFneo-D2, pEFneo-D3, pEFneo-V, pKS-IRF-3, or pKS-
T. Komatsu et al. / Virology 325 (2004) 137–148146IRF-3DN (50–100 ng/well)] together with pRL-TK-Luc
(5 ng/well), using the FuGENE 6 transfection reagent
(Roche Molecular Biochemicals). Luciferase activities in
the cell lysates were determined using a Dual-Glo Lucif-
erase assay system (Promega) according to the manufac-
turer’s protocol.
Preparation of a mammalian cell extract
Cells were lysed in NP-40 lysis buffer (50 mM Tris–
HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 10% glycerol, 1
mM EDTA, 1 mM Na3VO4) containing a protease inhibitor
cocktail (Sigma) (Suhara et al., 2000). After centrifugation,
the clarified supernatant was stored at 80 jC.
Western blot analysis
Western blot analysis was performed, as described pre-
viously (Gotoh et al., 1999), with an anti-IRF-3 antibody
(sc-9082) (Santa Cruz Biotechnology) or anti-SeV rabbit
serum. Western blot analysis with an anti-RGS-His antibody
(no. 34610) (Qiagen) was performed according to the
manufacturer’s protocol.
Native PAGE
The dimeric and monomer forms of IRF-3 were sepa-
rated by native-PAGE in the presence of 1% DOC, which
selectively dissociates CBP/p300 from the IRF-3 holocom-
plex containing CBP/p300, according to Iwamura et al.
(2001) (Suhara et al., 2000). Briefly, cell extracts (10–15
Ag protein) were diluted two times with the native sample
buffer (125 mM Tris–HCl, pH 6.8, 30% glycerol and 2%
DOC) and then separated on 7.5% polyacrylamide gel in
25 mM Tris and 192 mM glycine, pH 8.4, with and
without 1% DOC in the cathode and anode chamber,
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